FDA approves menopause treatment from Pfizer, Ligand

|About: Pfizer Inc. (PFE)|By:, SA News Editor

The FDA approves Pfizer's (PFE) Duavee for the treatment of moderate-to-severe hot flashes and for the prevention of post-menopausal osteoporosis.

PFE partner Ligand Pharmaceuticals (LGND) got a big boost from the news Thursday, rising 7%.

Notably, the drug is a selective estrogen receptor modulator combined with conjugated estrogens. Premarin is a conjugated estrogen tablet and made the news earlier this week after new research suggested there may be a link between the drug and the risk of blood clots.

Another FDA-approved post-menopausal osteoporosis drug is Eli Lilly's (LLY) Evista.